MedTrace Logo

Andosan in Allergic and Asthma Patients

NCT05192720 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-06-18

No results posted yet for this study

Summary

Examine whether daily oral ingestion of a immunomodulatory mushroom extract (AndoSanTM) in patients with asthma and allergy, undergoing allergen specific immunotherapy experience clinical and biochemical improvement in their disease.

A prospective randomised study comparing the mushroom extract with placebo.

Conditions

  • Allergic Asthma
  • Allergic Rhinoconjunctivitis
  • Immune Tolerance

Interventions

DIETARY_SUPPLEMENT

Andosan

See also detailed study design, Mushroom juice based on Agaricus Blazei and two other types of mushroom.

DIETARY_SUPPLEMENT

Placebo

drinking water with food colour

Sponsors & Collaborators

  • Oslo University Hospital

    collaborator OTHER

  • ImmunoPharma AS

    collaborator INDUSTRY

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Faiza Mahmood · University Hospital, Akershus

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-31
Primary Completion
2022-12-31
Completion
2023-02-28

Countries

  • Norway

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05192720 on ClinicalTrials.gov